HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use meloxicam oral suspension safely and effectively. See full prescribing information for meloxicam oral suspension.

Initial U.S. Approval: 2004

WARNING: RISK OF SERIOUS CARDIOVASCUI AR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning.

- eroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardio thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (5.1) · Meloxicam oral suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (4, 5.1) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history
- of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events (5.2)

RECENT MAJOR CHANGES

Warnings and Precautions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) (5.10) 04/2021 Warnings and Precautions, Fetal Toxicity (5.11)

INDICATIONS AND USAGE

Meloxicam oral suspension is a non-s roidal anti-inflammatory drug indicated for Osteoarthritis (OA) (1.1)

• Rheumatoid Arthritis (RA) (1.2)

• Juvenile Rheumatoid Arthritis (JRA) in patients 2 years of age or older (1.3)

DOSAGE AND ADMINISTRATION Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals

• 0A (2.2) and RA (2.3):

Starting dose: 7.5 mg once daily . Dose may be increased to 15 mg once daily

• JRA (2.4):

 0.125 mg/kg once daily up to a maximum of 7.5 mg. JRA dosing using the oral suspension should be individualized based on the weight of the child (2.4) · Meloxicam oral suspension is not interchangeable with approved formulations of oral meloxicam even if the total milligram strength is the same (2.6)

DOSAGE FORMS AND STRENGTHS

• Meloxicam oral suspension: 7.5 mg/5 mL (3)

CONTRAINDICATIONS

 Known hypersensitivity to meloxicam or any components of the drug product (4)
 History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4) In the setting of CABG surgery (4)

WARNINGS AND PRECAUTIONS

Hepatotoxicity: Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop (5.3)
 Hypertension; Patients taking some antihypertensive medications may have impaired response to these

- therapies when taking NSAIDs. Monitor blood pressure (5.4.7) Heart Failure and Edema. Avoid use of meloxicam oral suspension in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure (5.5)
- · Renal Toxicity: Monitor renal function in patients with renal or hepatic impairment, heart failure. dehvdration
- to the power of the process of the p
- Anaphylactic Reactions: Seek emergency help if an anaphylactic reaction occurs (5.7)
 Exacerbation of Asthma Related to Aspirin Sensitivity: Meloxicam oral suspension is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity)
- Serious Skin Reactions: Discontinue meloxicam oral suspension at first appearance of skin rash or other signs of hypersensitivity (5.9)
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); Discontinue and evaluate
- Fetal Toxicity: Limit use of NSAIDs, including meloxicam oral suspension, between about 20 to 30 weeks in pregnacy due to the risk of oligohydramnios/fetal renal dysfunction. Avoid use of NSAIDs in women at about program by due to the insk of engloyed animoso real dystarcials when due to include a control of the start of an and the start of the start of the start of engloyed animosof the start of the start of the start of engloyed animosof the start of the star
- Hematologic Toxicity: Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia (5.12, 7)

ADVERSE REACTIONS

 Most common (≥5% and greater than placebo) adverse events in adults are diarrhea, upper respiratory
tract infections, dyspepsia, and influenza-like symptoms (6.1) Adverse events observed in pediatric studies were similar in nature to the adult clinical trial experience (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Emerald Therapeutics, LLC at (800) 970-1991 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

DRUG INTERACTIONS

 <u>Drugs that Interfere with Hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs);</u> Monitor patients for bleeding who are concomitantly taking meloxicam oral suspension with drugs that interfere with hemostasis. Concomitant use of meloxicam oral suspension and analgesic doses of aspirin is not generally recommended (7)</u> ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers; Concomitant use with meloxicam oral suspension may diminish the antihypertensive effect of these drugs. Monitor blood pressure (7)
 ACE Inhibitors and ARBs; Concomitant use with meloxicam oral suspension in elderly, volume-depleted, or

those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor

 biuretics: NSAIDs can reduce nativuetic effect of furosemide and thiazide divertics. assure diuretic efficacy including antihypertensive effects (7)

USE IN SPECIFIC POPULATIONS

. Infertility: NSAIDs are associated with reversible infertility. Consider withdrawal of meloxicam oral suspension in who have difficulties conceiving (8.3)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

1 INDICATIONS AND USAGE

C-A235

Rx Only

NDC 72919-124-10

тнекарептіся, і і с

<u>Հ.Տ. ազ/ծա Շ.հ</u>

Oral Suspension, USP

Meloxicam

Meloxicam

Oral Suspension, USP

7.5 mg/5 mL

EMERALD

NDC 72919-124-10

Rx Only

C-A235

1.1 Osteoarthritis (OA) 1.2 Rheumatoid Arthritis (RA) 1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course 2 DOSAGE AND ADMINISTRATION 2.1 General Dosing Instructions

- 2.2 Osteoarthritis 2.3 Rheumatoid Arthritis 2.4 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course
- 2.5 Renal Impairment 2.6 Non-Interchangeability with Other Formulations of Meloxicam
- **3 DOSAGE FORMS AND STRENGTHS**

4 CONTRAINDICATIONS **5 WARNINGS AND PRECAUTIONS**

5.1 Cardiovascular Thrombotic Events trointestinal Bleeding, Ulceration, and Perforation

- 5.3 Hepatotoxicity
- 5.4 Hypertension
- 5.6 Renal Toxicity and Hyperkalemia
- 5.7 Anaphylactic Reactions
- 5.8 Exacerbation of Asthma Related to Aspirin Sensitivity 5.9 Serious Skin Reactions
- 5.10 Drug Beaction with Epsinophilia and Systemic Symptoms (DRESS)
- 5.11 Fetal Toxicity 5.12 Hematologic Toxicity
- 5.13 Masking of Inflammation and Fever
- 5 14 Laboratory Monitorin **6 ADVERSE REACTIONS**
- 6.1 Clinical Trials Experience
- 7 DRUG INTERACTIONS
- **8 USE IN SPECIFIC POPULATIONS**
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment
- 8 7 Renal Imn 10 OVERDOSAGE
- 11 DESCRIPTION
- 12 CLINICAL PHARMACOLOGY
- 12.1 Mechanism of Actior
- 12.3 Pharmacokinetic
- 13 NONCLINICAL TOXICOLOGY
- nesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES
- 14.1 Osteoarthritis and Rheumatoid Arthritis 14.2 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course

16 HOW SUPPLIED/STORAGE AND HANDLING **17 PATIENT COUNSELING INFORMATION**

* Sections or subsections omitted from the full prescribing information are not listed

FULL PRESCRIBING INFORMATION

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

- WARNING, INC. 5 Sector Cardiovascular Thrombotic Events

 Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular

 Unsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular botic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions (5.1)]. Meloxicam oral suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1)]. astrointestinal Bleeding, Ulceration, and Perforation
- NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur al any time during use and without warning symptoms. Elderly patients and patients with a prior histor of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings and Precautions (5.2)].

1 INDICATIONS AND USAGI

1.1 Osteoarthritis (OA Meloxicam oral suspension is indicated for relief of the signs and symptoms of osteoarthritis [see Clinical Studies (14.1)].

1.2 Rheumatoid Arthritis (RA)

Meloxicam oral suspension is indicated for relief of the signs and symptoms of rheumatoid arthritis [see Clinical Studies (14.1)].

1.3 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course Meloxicani oral suspension is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age and older [see Clinical Studies (14.2]].

2 DOSAGE AND ADMINISTRATION

2.1 General Dosing Instructions

Carefully consider the potential benefits and risks of meloxicam oral suspension and other treatment options before deciding to use meloxicam oral suspension. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5)]. After observing the response to initial therapy with meloxicam oral suspension, adjust the dose to suit an

individual patient's needs. In adults, the maximum recommended daily oral dose of meloxicam oral suspension is 15 mg regardless of formulation. In patients with hemotilayis, a maximum daily dosage of 7.5 mg is recommended *[see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]*. Meloxicam oral suspension 7.5 mg/5 mL or 15 mg/10 mL may be substituted for meloxicam tablets 7.5 mg

or 15 mg, respectively. Shake the oral suspension gently before using.

Meloxicam oral suspension may be taken without regard to timing of meals.

2.2 Osteoarthritis

For the relief of the signs and symptoms of osteoarthritis the recommended starting and maintenance oral dose of meloxicam oral suspension is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.

2.3 Rheumatoid Arthritis

36 kg (80 lb)

8 kg (106 lb

60 kg (132 l

2.5 Renal Impairment

Clinical Pharmacology (12.3)].

3 DOSAGE FORMS AND STRENGTHS

Meloxicam oral suspension

4 CONTRAINDICATIONS

Precautions (5.7, 5.8)]

Post-MI Patients

5 WARNINGS AND PRECAUTIONS

5.1 Cardiovascular Thrombotic Events

sk has been observed most consistently at higher dose

contraindicated in the setting of CABG [see Contraindications (4)].

recent MI, monitor patients for signs of cardiac ischemia.

short-term NSAID therapy is not without risk.

5.2 Gastrointestinal Bleeding, Ulceration, and Perforation

Revised: 04/2022

For the relief of the signs and symptoms of rheumatoid arthritis, the recommended starting and maintenance oral dose of meloxicam oral suspension is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.

2.4 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course

To improve dosing accuracy in smaller weight children, the use of the meloxicam oral suspension is recom-mended. Meloxicam oral suspension is available in the strength of 7.5 mg/5 mL. For the treatment of juvenile rheumatoid arthritis, the recommended oral dose of meloxicam oral suspension is 0.125 mg/kg once daily up to a maximum of 7.5 mg. There was no additional benefit demonstrated by increasing the dose above 0.125 mg/kg once daily in these clinical trial

0.125 mg/kg

oxicam oral suspension in subjects with severe renal impairment is not recommended The use of meloxicam oral suspension in subjects with severe renal impairment is not recommended. In patients on hemodialysis, the maximum dosage of meloxicam oral suspension is 7.5 mg per day [see

Meloxicam oral suspension has not shown equivalent systemic exposure to other approved formulations of oral meloxicam. Therefore, meloxicam oral suspension is not interchangeable with other formulations of oral meloxicam product even if the total milligram strength is the same. Do not substitute similar dose strengths of

Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product [see Warnings and Precautions (5.7, 5.9)]

• In the setting of coronary artery bypass graft (CABG) surgery [see Warnings and Precautions (5.1)]

· History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe,

Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have show

an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and

an increased risk of senious candowscular (cv) informous events, including infocation initiation (with and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID

use appears to be similar in those with and without known CV disease or risk factors for CV disease. However,

of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic

becapped a doe similar in the of the does not an off and the second rest and the second of the second and the second seco

To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective

There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV

thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as meloxicam, increases the risk of serious gastrointestinal (GI) events [see Warnings and Precautions (5.2)].

Status Post Coronary Artery Bypass Graft (CABG) Surgery Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10-14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are

bservational studies conducted in the Danish National Registry have demonstrated that patients treated with

Observational source of the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post-MI

was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID

Avoid the use of meloxicam oral suspension in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If meloxicam oral suspension is used in patients with a

NSAIDs, including meloxicam, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients

treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper Glulcers, gross bleeding, or perforation caused by ISAIb sourced in a pproximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for one year. However, even

increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.

nts. Although the absolute rate of death declined somewhat after the first year post-MI, the

should be informed about the symptoms of serious CV events and the steps to take if they occur

dose for the shortest duration possible. Physicians and patients should remain alert for the development of

such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients

netimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and

Delivered dose

1.5 mg

4.5 mo

6.0 mg

3.0 mg

Juvenile Rheumatoid Arthritis dosing using the oral suspension should be individualized based on the weight of the child:

(1.5 mg/mL)

3.0 m

50 m

2.6 Non-Interchangeability with Other Formulations of Meloxicam

meloxicam oral suspension with other formulations of oral meloxicam product.

Meloxicam oral suspension is contraindicated in the following patients:

• yellowish green tinged viscous suspension containing 7.5 mg meloxicam per 5 mL.

<u>Risk Factors for GI Bleeding, Ulceration, and Perforation</u> Patients with a prior history of peptic ulcer disease and/or GI bleeding who used NSAIDs had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy. concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. Most postmarketing reports of fatal GI events occurred in elderly or debilitated patients. Additionally, patients with advanced liver disease

Strategies to Minimize the GI Risks in NSAID-treated patients:

and/or coagulopathy are at increased risk for GI bleeding.

Use the lowest effective dosage for the shortest possible
Avoid administration of more than one NSAID at a time.

for evidence of GI bleeding [see Drug Interactions (7)].

therapies when taking NSAIDs [see Drug Interactions (7)].

5.5 Heart Failure and Edema

5.6 Renal Toxicity and Hyperkalemia

function [see Clinical Pharmacology (12.3)].

Seek emergency help if an anaphylactic reaction occurs.

Hyperkalemia

5.7 Anaphylactic Reactions

5.9 Serious Skin Reactions

to NSAIDs Isee Contraindications (4)].

suspension and evaluate the patient immediately

Premature Closure of Fetal Ductus Arteriosus

Oligohydramnios/Neonatal Renal Impairment

5.11 Fetal Toxicity

dialysis were required.

Populations (8.1)].

5.12 Hematologic Toxicity

5.13 Masking of Inflammation and Fever

Precautions (5.8)].

failure, and death.

Renal Toxicity

5.3 Hepatotoxicity

including meloxicam.

· Avoid use in patients at higher risk unless benefits are expected to outweigh the increased risk of bleeding Providues in patients at ingline instrumess of expected to outweight the interease instruments are expected to outweight the interease instruments are expected to outweight the interease of the instruments are expected to outweight the interease of the instruments are expected to outweight the interease of the instruments are expected to outweight the interease of the instruments are expected to outweight the interease of the instruments are expected to outweight the interease of the instruments are expected to outweight the instruments are expected to outw If a serious GL adverse event is suspected, promotly initiate evaluation and treatment, and discontinue

In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely
 In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely

Elevations of ALT or AST (three or more times the upper limit of normal [ULN]) have been reported in approximately 1% of NSAID-treated patients in clinical trials. In addition, rare, sometimes fatal, cases of severe hepatic injury, including fulminant hepatitis, liver necrosis, and hepatic failure have been reported.

Elevations of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs

Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue meloxicam oral suspension immediately, and perform a clinical evaluation of the patient [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

5.4 Hypertension NSAIDs, including meloxicam oral suspension, can lead to new onset or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking angiotensin erting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these

Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy.

The Coxib and traditional NSAID Trialists' Collaboration meta-analysis of randomized controlled trials demon-strated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for hear

Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of meloxicam may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) [see Drug Interactions (7)].

Avoid the use of meloxicam oral suspension in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If meloxicam oral suspension is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.

Long-term administration of NSAIDs, including meloxicam oral suspension, has resulted in renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury.

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent maintenance of retraction, in these patients, animitation of an installation can be a dose-rependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly ntinuation of NSAID therapy is usually followed by recovery to the pretrea

The renal effects of meloxicam oral suspension may hasten the progression of renal dysfunction in patients with preexisting renal disease. Because some meloxicam oral suspension metabolites are excreted by the kidney, monitor patients for signs of worsening renal function.

Correct volume status in dehydrated or hypovolemic patients prior to initiating meloxicam oral suspension. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of meloxicam oral suspension [see Drug Interactions (7)].

No information is available from controlled clinical studies regarding the use of meloxicam oral suspension in renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If meloxicam or all suspension in patients with advanced renal disease, monitor patients for signs of worsening renal function. If meloxicam or all suspension is used in patients with advanced renal disease, monitor patients for signs of worsening renal suspension is used in patients with advanced renal disease, monitor patients for signs of worsening renal suspension is used in patients with advanced renal disease.

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs. even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.

Meloxicam has been associated with anaphylactic reactions in patients with and without known hypersensitivity to meloxicam and in patients with aspirin-sensitive asthma [see Contraindications (4) and Warnings and

5.8 Exacerbation of Asthma Related to Aspirin Sensitivity

A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhi-nosinusitis complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs. Because cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, meloxicam oral suspension is contraindicated in patients with this form of aspirin sensitivity [see Contraindications (4)]. When meloxicam oral suspension is used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma.

NSAIDs, including meloxicam, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolvsis (TEN), which can be fatal. These serious event ay occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of meloxicam oral suspension at the first appearance of skin rash or any other sign of hypersensitivity, meloxicam oral suspension is contraindicated in patients with previous serious skin reactions

5.10 Drug Reaction with Fosinophilia and Systemic Symptoms (DRESS)

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as meloxicam oral suspension. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue meloxicam oral

Letitatule clusure on real cuarter real and the second sec

Use of NSAIDs, including meloxicam oral suspension, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impai These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation.

Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligobydramnios may for example include limb contractures and delayed lung maturation. In some teting cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit meloxicam oral suspension use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if meloxicam oral suspension treatment extends beyond 48 hours. Discontinue meloxicam oral suspension if oligohydramnios occurs and follow up according to clinical practice [see Use in Specific

Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with meloxicam oral suspension has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.

NSAIDs, including meloxicam oral suspension, may increase the risk of bleeding events, Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [see Drug Interactions (7)].

5.14 Laboratory Monitoring

Because serious GI bleeding, hepatotoxicity, and renal injury can occur without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment with a CBC and a chemistry profile periodically [see Warnings and Precautions (5.2, 5.3, 5.6)].

6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the labeling: • Cardiovascular Thrombotic Events [see Boxed Warning and Warnings and Precautions (5.1)] • GI Bleeding, Ulceration, and Perforation [see Boxed Warning and Warnings and Precautions (5.2)] Hepatotoxicity [see Warnings and Precautions (5.3)]
Hypertension [see Warnings and Precautions (5.4)]

Heart Failure and Edema [see Warnings and Precautions (5.5)]

Renal Toxicity and Hyperkalemia [see Warnings and Precautions (5.6)]
Anaphylactic Reactions [see Warnings and Precautions (5.7)] Serious Skin Reactions [see Warnings and Precautions (5.9)]

Hematologic Toxicity [see Warnings and Precautions (5.12)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Osteoarthritis and Rheumatoid Arthritis

The meloxicam Phase 2/3 clinical trial database includes 10,122 OA patients and 1012 RA patients treated with meloxicam 7.5 mg/day, 3505 OA patients and 1351 RA patients treated with meloxicam 15 mg/day. Meloxicam at these doses was administered to 661 patients for at least 6 months and to 312 patients for at Meiowam at these topses was administered to or patients for a test or monitors and to or patients for at least one year. Approximately 10,500 of these patients were treated in ten placebo- and/or active-controlled osteoarthritis trials and 2363 of these patients were treated in ten placebo- and/or active-controlled rheumatoid arthritis trials. Gastrointestinal (GI) adverse events were the most frequently reported adverse events in all treatment groups across meloxicam trials. A 12-week multicenter, double-blind, randomized trial was conducted in patients with osteoarthritis of the

knee or hip to compare the efficacy and safety of meloxicam with placebo and with an active control. Two 12-week multicenter, double-blind, randomized trials were conducted in patients with rheumatoid arthritis to compare the efficacy and safety of meloxicam with placebo.

Table 1a depicts adverse events that occurred in \ge 2% of the meloxicam treatment groups in a 12-week placebo-and active-controlled osteoarthritis trial.

Table 1b depicts adverse events that occurred in \ge 2% of the meloxicam treatment groups in two 12-week placebo-controlled rheumatoid arthritis trials

Table 1a Adverse Events (%) Occurring in ≥2% of Meloxicam Patients in a 12-Week Osteoarthritis Placebo-and Active-Controlled Trial

	Placebo	Meloxicam	Meloxicam	Diclofenac
		7.5 mg daily	15 mg daily	100 mg daily
No. of Patients	157	154	156	153
Gastrointestinal	17.2	20.1	17.3	28.1
Abdominal pain	2.5	1.9	2.6	1.3
Diarrhea	3.8	7.8	3.2	9.2
Dyspepsia	4.5	4.5	4.5	6.5
Flatulence	4.5	3.2	3.2	3.9
Nausea	3.2	3.9	3.8	7.2
Body as a Whole				
Accident household	1.9	4.5	3.2	2.6
Edema ¹	2.5	1.9	4.5	3.3
Fall	0.6	2.6	0.0	1.3
Influenza-like symptoms	5.1	4.5	5.8	2.6
Central and Peripheral				
Nervous System				
Dizziness	3.2	2.6	3.8	2.0
Headache	10.2	7.8	8.3	5.9
Respiratory				
Pharyngitis	1.3	0.6	3.2	1.3
Upper respiratory				
tract infection	1.9	3.2	1.9	3.3
Skin				
Rash ²	2.5	2.6	0.6	2.0

² WHO preferred terms rash, rash erythematous, and rash maculo-papular combined

Table 1b Adverse Events (%) Occurring in ≥2% of Meloxicam Patients in Two 12-Week Rheumatoid Arthritis Placebo-Controlled Trials

	Placebo	Meloxicam 7.5 mg daily	Meloxicam 15 mg daily
No. of Patients	469	481	477
Gastrointestinal Disorders	14.1	18.9	16.8
Abdominal pain NOS ²	0.6	2.9	2.3
Dyspeptic signs and symptoms ¹	3.8	5.8	4.0
Nausea ²	2.6	3.3	3.8
General Disorders and Administration	on Site Conditions		
Influenza-like illness ²	2.1	2.9	2.3
Infection and Infestations			
Upper respiratory tract infections-			
pathogen class unspecified ¹	4.1	7.0	6.5
Musculoskeletal and Connective Tis	sue Disorders		
Joint related signs and symptoms ¹	1.9	1.5	2.3
Nervous System Disorders			
Headaches NOS ²	6.4	6.4	5.5
Skin and Subcutaneous Tissue Diso	rders		
Rash NOS ²	1.7	1.0	2.1

¹ MedDRA high level term (preferred terms): dyspeptic signs and symptoms (dyspepsia, dyspepsia aggravated, eructation, gastrointestinal irritation), upper respiratory tract infections-pathogen unspecified (laryngitis NOS, pharyngitis NOS, sinusitis NOS), joint related signs and symptoms (arthralgia, arthralgia aggravated, joint on, joint effusion, joint swelling) MedDRA preferred term: nausea, abdominal pain NOS, influenza-like illness, headaches NOS, and rash NOS

The adverse events that occurred with meloxicam oral suspension in \ge 2% of patients treated short-term (4 to 6 weeks) and long-term (6 months) in active-controlled osteoarthritis trials are presented in Table 2.

Table 2 Adverse Events (%) Occurring in ${\geq}2\%$ of Meloxicam Patients in 4 to 6 Weeks and 6 Month Active-Controlled Osteoarthritis Trials

	4 to 6 Weeks Co		6 Month Contro	
	Meloxicam	Meloxicam	Meloxicam	Meloxicam
	7.5 mg daily	15 mg daily	7.5 mg daily	15 mg daily
No. of Patients	8955	256	169	306
Gastrointestinal	11.8	18.0	26.6	24.2
Abdominal pain	2.7	2.3	4.7	2.9
Constipation	0.8	1.2	1.8	2.6
Diarrhea	1.9	2.7	5.9	2.6
Dyspepsia	3.8	7.4	8.9	9.5
Flatulence	0.5	0.4	3.0	2.6
Nausea	2.4	4.7	4.7	7.2
Vomiting	0.6	0.8	1.8	2.6
Body as a Whole				
Accident household	0.0	0.0	0.6	2.9
Edema ¹	0.6	2.0	2.4	1.6
Pain	0.9	2.0	3.6	5.2
Central and Peripheral Nervous System				
Dizziness	1.1	1.6	2.4	2.6
Headache	2.4	2.7	3.6	2.6
Hematologic				
Anemia	0.1	0.0	4.1	2.9
Musculoskeletal				
Arthralgia	0.5	0.0	5.3	1.3
Back pain	0.5	0.4	3.0	0.7
Psychiatric				
Insomnia	0.4	0.0	3.6	1.6
Respiratory				
Coughing	0.2	0.8	2.4	1.0
Upper respiratory				
tract infection	0.2	0.0	8.3	7.5
Skin				
Pruritus	0.4	1.2	2.4	0.0
Rash 2	0.3	1.2	3.0	1.3
Urinary		.=		
Micturition frequency	0.1	0.4	2.4	1.3
Urinary tract infection	0.3	0.4	4.7	6.9

WHO preferred terms edema, edema dependent, edema peripheral, and edema legs combined ² WHO preferred terms rash, rash erythematous, and rash maculo-papu

Higher doses of meloxicam (22.5 mg and greater) have been associated with an increased risk of serious GI vents; therefore, the daily dose of meloxicam oral suspension should not exceed 15 mg.

Pauciarticular and Polyarticular Course Juvenile Rheumatoid Arthritis (JRA)

Three hundred and eighty-seven patients with pauciarticular and polyaritular course JRA were exposed to meloxicam with doses ranging from 0.125 to 0.375 mg/kg per day in three clinical trials. These studies consisted of two 12-week multicenter, double-blind, randomized trials (new with a 12-week open-label extension) and one with a 40-week extension) and one 1-year open-label PK study. The adverse events observed in these pediatric studies with meloxicam were similar in nature to the adult clinical trial experience, although there were differences in frequency. In particular, the following most common adverse events, abdominal pain, vomiting, diarrhea, headache, and pyrexia, were more common in the pediatric than in the adult trials. Rash was reported in seven (<2%) patients receiving meloxicam. No unexpected adverse events were identified during the course of the trials. The adverse events did not demonstrate an age or gender-specific subgroup

The following is a list of adverse drug reactions occurring in $<\!2\%$ of patients receiving meloxicam in clinical trials involving approximately 16,200 patients.

allergic reaction, face edema, fatigue, fever, hot flushes,

Body as a Whole

	malaise, syncope, weight decrease, weight increase
Cardiovascular	angina pectoris, cardiac failure, hypertension, hypotension,
	myocardial infarction, vasculitis
Central and Peripheral Nervous	
System	convulsions, paresthesia, tremor, vertigo
Gastrointestinal	colitis, dry mouth, duodenal ulcer, eructation, esophagitis, gastric
	ulcer, gastritis, gastroesophageal reflux, gastrointestinal hemor-
	rhage, hematemesis, hemorrhagic duodenal ulcer, hemorrhagic
	gastric ulcer, intestinal perforation, melena, pancreatitis,
	perforated duodenal ulcer, perforated gastric ulcer, stomatitis
	ulcerative
Heart Rate and Rhythm	arrhythmia, palpitation, tachycardia
Hematologic	leukopenia, purpura, thrombocytopenia
Liver and Biliary System	ALT increased, AST increased, bilirubinemia, GGT increased,
	hepatitis
Metabolic and Nutritional	dehydration
Psychiatric	abnormal dreaming, anxiety, appetite increased, confusion,
	depression, nervousness, somnolence
Respiratory	asthma, bronchospasm, dyspnea
Skin and Appendages	alopecia, angioedema, bullous eruption, photosensitivity
	reaction, pruritus, sweating increased, urticaria
Special Senses	abnormal vision, conjunctivitis, taste perversion, tinnitus
Urinary System	albuminuria, BUN increased, creatinine increased, hematuria,

6.2 Postmarketing Experience

The following adverse reactions have been identified during post approval use of meloxicam. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions about whether to include an adverse vent from spontaneous reports in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (2) number of reports, or (3) strength of causal relationship to the drug. Adverse reactions reported in worldwide post marketing experience or the literature include: acute urinary retention; agranulocytosis; alterations in mood (such as mood elevation); anaphylaciotic reactions including shock; erythema multiforme; exfoliative dermatitis; interstitial nephritis; jaundice; liver failure; Stevens-Johnson syndrome; toxic epidermal necrolysis, and infertility female.

renal failure

7 DRUG INTERACTIONS

See Table 3 for clinically significant drug interactions with meloxicam. See also Warnings and Precautions (5.2, 5.6, 5.12) and Clinical Pharmacology (12.3).

Table 3 Clinically Significant Drug Interactions with Meloxican

Drugs that Interfere with Hemostasis

Clinical Impac

 Meloxicam and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of meloxicam and anticoagulants have an increased risk of serious bleeding compared to the use of either

drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiolog icid studies showed that commitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.

Monitor patients with concomitant use of meloxicam oral suspension with anticoagulants (e.g., warfarin), artiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotoni reuptake inhibitors (SNRIs) for signs of bleeding [see Warnings and Precautions (5.12]].

Aspirin

Clinical Impact: Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [see Warnings and Precautions (5.2)].

Intervention.

Concomitant use of meloxicam oral suspension and low dose aspirin or analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see Warnings and Precautions (5.12)]. oxicam oral suspension is not a substitute for low dose aspirin for cardiovascular protection.

ACE Inhibitors, Angiotensin Receptor Blockers, or Beta-Blockers

Clinical Impact. NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angio In patients who are elderly, volume-depleted (including those on diuretic thrapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function. including possible acute renal failure. These effects are usually reversible

• During concomitant use of meloxicam oral suspension and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained blod pressure to ensure that use of meloxicam oral suspension and ACE inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function *[see*] Warnings and Precautions (5.6)1.

When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter.

Diuretics Clinical Impact

Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis. However, studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect. Furosemula signature and multiple namics and pharmacokinetics are not affected by multiple doses of meloxicam.

During concomitant use of meloxicam oral suspension with diuretics, observe patients for signs of worsening enal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.6)].

Lithium

Clinical Impact: NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis [see Clinical Pharmacology (12.3)].

Intervention

During concomitant use of meloxicam oral suspension and lithium, monitor patients for signs of lithium toxicity.

Methotrexate

Clinical Impact. Concomitant use of NSAIDs and methotrexate may increase the risk of methotrexate toxicity (e.g., neutrope nia, thrombocytopenia, renal dysfunction).

Intervention

During concomitant use of meloxicam oral suspension and methotrexate, monitor patients for methotrexate

Cyclosporine

Clinical Impact Concomitant use of meloxicam and cyclosporine may increase cyclosporine's nephrotoxicity.

During concomitant use of meloxicam oral suspension and cyclosporine, monitor patients for signs of worsening renal function

NSAIDs and Salicylates

Clinical Impact Concomitant use of meloxicam with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see Warnings and Precautions (5.2)].

Intervention: The concomitant use of meloxicam oral suspension with other NSAIDs or salicvlates is not recommended.

Pemetrexed

Clinical Impact Concomitant use of meloxicam and pemetrexed may increase the risk of pemetrexed-associated nyelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information)

During concomitant use of meloxicam oral suspension and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.

Patients taking meloxicam should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.

In patients with creatinine clearance below 45 mL/min, the concomitant administration of meloxicam with pemetrexed is not recommended.

Sodium Polystyrene Sulfonate

Clinical Impact: Cases of intestinal necrosis (possibly fatal) have been described in patients who received concomitant sorbitol and sodium polystyrene sulfonate. Due to the presence of sorbitol in meloxicam oral suspension, use with sodium polystyrene sulfonate is not recommended.

The concomitant use of meloxicam oral suspension with sodium polystyrene sulfonate is not recommended.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Use of NSAIDs, including meloxicam oral suspension, can cause premature closure of the fetal ductus arterices on de los, including including and a copyright policy of the policy weeks of gestation, and avoid meloxicam oral suspension use at about 30 weeks of gestation and later in pregnancy (see Clinical Considerations. Data)

Premature Closure of Fetal Ductus Arteriosus

Use of NSAIDS, including meloxicam oral suspension, at about 30 weeks gestation or later in pregnancy increases the risk of premature closure of the fetal ductus arteriosus.

Oligohydramnios/Neonatal Renal Impairment Use of NSAIDs at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment.

Data from observational studies regarding other potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive. In animal reproduction studies, embryofetal death was observed in rats and rabbits treated during the period of organogenesis with meloxicam at oral doses equivalent to 0.65- and 6.5-times the maximum recommended human dose (MRHD) of meloxicam oral suspension. Increased incidence of septal heart defects were observed in rabbits treated throughout embryosepersis with meloxicam at an oral dose equivalent to 78-times the MRHD. In pre- and post-natal reproduction studies, there was an increased incidence of dystocia, delayed parturition, and decreased offspring survival at 0.08-times MRHD of meloxicam. No teratogenic effects were observed in rats and rabbits treated with neloxicam during organogenesis at an oral dose equivalent to 2.6 and 26-times the MRHD [see Data]

Based on animal data, prostaglanding have been shown to have an important role in endometrial vascular base of namina one protogramma nav been along to have all important to be in choice of the along a second period with the second also have been shown to have an important role in fetal kidney development. In published animal studies rostaglandin synthesis inhibitors have been reported to impair kidney development when administered at clinically relevant doses.

The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically ecognized pregnancies is 2% to 4% and 15% to 20%, respectively

Clinical Considerations

Fetal/Neonatal Adverse Reactions Premature Closure of Fetal Ductus Arteriosus: Avoid use of NSAIDs in women at about 30 weeks cestation and later in pregnancy, because NSAIDs, includng meloxicam oral suspension, can cause premature closure of the fetal ductus arteriosus (see Data)

Oligohydramnios/Neonatal Renal Impairment:

If an NSAID is necessary at about 20 weeks gestation or later in pregnancy, limit the use to the lowest effec-tive dose and shortest duration possible. If meloxicam oral suspension treatment extends beyond 48 hours, consider monitoring with ultrasound for oligohydramnios. If oligohydramnios occurs, discontinue meloxicam oral suspension and follow up according to clinical practice (see Data).

Labor or Deliverv There are no studies on the effects of meloxicam oral suspension during labor or delivery. In animal studies, NSAIDs, including meloxicam, inhibit prostaglandin synthesis, cause delayed parturition, and increase the incidence of stillbirth.

Human Data

Premature Closure of Fetal Ductus Arteriosus: Published literature reports that the use of NSAIDs at about 30 weeks of gestation and later in pregnancy may

cause premature closure of the fetal ductus arteriosus

Oligohydramnios/Neonatal Renal Impairment: Published studies and postmarketing reports describe maternal NSAID use at about 20 weeks gestation or I ability of a social and postinitarian report a destination matchina include use at about 20 more granting report a destination in a destination and the social and the so although oligophydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. In many

cases, but not all, the decrease in amnitor full water ransient and reversible with cession of the drug. There have been a limited number of case reports of maternal NSAID use and neonatal renal dysfunction without oligohydramnios, some of which were irreversible. Some cases of neonatal renal dysfunction required tment with invasive procedures, such as exchange transfusion or dialysis

Methodological limitations of these postmarketing studies and reports include lack of a control group; limited Information regarding dose, duration, and timing of drug exposure; and concomitant use of other medications. These limitations preclude establishing a reliable estimate of the risk of adverse fetal and neonatal outcomes with maternal NSAID use. Because the published safety data infants, the generalizability of certain reported risks to the fullterm infant exposed to NSAIDs through materna use is uncertain

Meloxicam was not teratogenic when administered to pregnant rats during fetal organogenesis at oral doses up to 4 mg/kg/day (2.6-fold greater than the MRHD of 15 mg of meloxicam based on BSA comparison). inistration of meloxicam to pregnant rabbits throughout embryogenesis produced an increased incidence of septal defects of the heart at an oral dose of 60 mg/kg/day (78-fold greater than the MRHD based on BSA comparison). The no effect level was 20 mg/kg/day (26-fold greater than the MRHD based on BSA version). In rats and rabbits, embryolethality occurred at oral meloxicam doses of 1 mg/kg/day and 5 mg/ kg/day, respectively (0.65- and 6.5-fold greater, respectively, than the MRHD based on BSA comparison) when administered throughout organogenesis

Oral administration of meloxicam to pregnant rats during late gestation through lactation increased the incidence of dystocia, delayed parturition, and decreased offspring survival at meloxicam doses of 0.125 mg/ kg/day or greater (0.08-times MRHD based on BSA comparison).

8.2 Lactation

Risk Summary

There are no human data available on whether meloxicam is present in human milk, or on the effects or breastfed infants, or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for meloxicam oral suspension and any potential adverse effects on the breastfed infant from the meloxicam oral suspension or from the underlying maternal condition.

Animal Data

Meloxicam was present in the milk of lactating rats at concentrations higher than those in plasma.

8.3 Females and Males of Reproductive Potential

Infertility

Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including meloxicam oral suspension, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. Published animal studies haves, man has been advanted and a studies have a shown that administration of prostaglandin synthesis inhibitors has the potential to disrupt prostaglandin-mediated follicular rupture required for ovulation. Small studies in women treated with NSAIDs have also shown a reversible delay in ovulation. Consider withdrawa of NSAIDs, including meloxicam oral suspension, in women who have difficulties conceiving or who are undergoing investigation of infertility.

8.4 Pediatric Use

The safety and effectiveness of meloxicam in pediatric JRA patients from 2 to 17 years of age has been aluated in three clinical trials [see Dosage and Administration (2.3), Adverse Reactions (6.1) and Clinical Studies (14.2)].

8.5 Geriatric Use

Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascu Larg gastrolitestical, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects [see Warnings and Precautions (5.1, 5.2, 5.3, 5.6, 5.14)].

8.6 Hepatic Impairment

No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment have not been adequately studied. Since meloxicam is significantly metabolized in the liver and hepatotoxicity may occur, use meloxicam with caution in patients with hepatic impairment [see Warnings nd Precautions (5.3) and Clinical Pharmacology (12.3)].

8.7 Renal Impairment

No dose adjustment is necessary in patients with mild to moderate renal impairment. Patients with severe renal impairment have not been studied. The use of meloxicam oral suspension in subjects with severe renal impairment is not recommended. In patients on hemodialysis, meloxican soup on the second recent of the other of a Meloxicam is not dialyzable [see Dosage and Administration (2.1) and Clinical Pharmacology (12.3)].

10 OVERDOSAGE

Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, synchronized and epigastric pain, which have been generally versible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred, but were rare [see Warnings and Precautions (5.1, 5.2, 5.4, 5.6)].


Manage patients with symptomatic and supportive care following an NSAID overdosage. There are no specific antidotes. Consider emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 grams per kg of body weight in pediatric patients) and/or osmotic cathartic in symptomatic patients see within four hours of ingestion or in patients with a large overdosage (5 to 10 times the recommended dosage). Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.

There is limited experience with meloxicam overdosage. Cholestyramine is known to accelerate the clearance of meloxicam. Accelerated removal of meloxicam by 4 g oral doses of cholestyramine given three times a day was demonstrated in a clinical trial. Administration of cholestyramine may be useful following an overdosage

For additional information about overdosage treatment, call a poison control center (1-800-222-1222).

11 DESCRIPTION

Meloxicam oral suspension, USP is a nonsteroidal anti-inflammatory drug (NSAID). Each bottle of meloxicam oral suspension contains 7.5 mg meloxicam per 5 mL. Meloxicam is chemically designated as 4-hydroxy-2-methyl-*N*-(5-methyl-2-thiazolyl)-2/H-1,2-benzothiazine-3-carboxamide-1,1-dioxide. The molecular weight is 351.4. Its empirical formula is C_{14} H₁₃ N₃O₄ S₂ and it has the following structural formula:



Meloxicam, is a pastel yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. It is very slightly soluble in methanol. Meloxicam has an apparent partition coefficien (log P) app = 0.1 in n-octanol/buffer pH 7.4. Meloxicam has pKa values of 1.1 and 4.2.

Meloxicam is available as an oral suspension containing 7.5 mg meloxicam per 5 mL

The inactive ingredients in meloxicam oral suspension include colloidal silicon dioxide, hydroxyethylcellulose sorbitol, glycerol, xylitol, monobasic sodium phosphate (dihydrate), saccharin sodium, sodium benzoate, citric acid (monohydrate), raspberry flavor, and purified water

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Meloxicam has analgesic, anti-inflammatory, and antipyretic properties

The mechanism of action of meloxicam oral suspension, like that of other NSAIDs, is not completely undertood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

Meloxicam is a potent inhibitor of prostaglandin synthesis in vitro. Meloxicam concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize affreent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because meloxicam is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues

12.3 Pharmacokinetics

Absorption

The absolute bioavailability of meloxicam capsules was 89% following a single oral dose of 30 mg compared with 30 mg IV bolus injection. Following single intravenous doses, dose-proportional pharmacokinetics were shown in the range of 5 mg to 60 mg. After multiple oral doses the pharmacokinetics of meloxicam capsules were dose-proportional over the range of 7.5 mg to 15 mg. Mean C_{max} was achieved within four to five hours after a 7.5 mg meloxicam tablet was taken under fasted conditions, indicating a prolonged drug absorption. With multiple dosing, steady-state concentrations were reached by Day 5. A second meloxicam concentration peak occurs around 12 to 14 hours post-dose suggesting biliary recycling

Meloxicam oral suspension doses of 7.5 mg/5 mL and 15 mg/10 mL have been found to be bioequivalent to neloxicam 7.5 mg and 15 mg capsules, respectively. Meloxicam capsules have been shown to be bioequivalent to meloxicam tablets

Table 4 Single Dose and Steady-State Pharmacokinetic Parameters for Oral 7.5 mg and 15 mg Meloxicam (Mean and % CV)¹

		Steady State	е		Single Dose	
Pharm	acokinetic	Healthy male Parameters	Elderly males adults	Elderly females	Renal failure	Hepatic insufficiency
(% CV))	(Fed) ²	(Fed) ²	(Fed) ²	(Fasted)	(Fasted)
		7.5 mg ³	15 mg	15 mg	15 mg	15 mg
		tablets	capsules	capsules	capsules	capsules
N		18	5	8	12	12
C _{max}	[µg/mL]	1.05 (20)	2.3 (59)	3.2 (24)	0.59 (36)	0.84 (29)
t _{max}	[h]	4.9 (8)	5 (12)	6 (27)	4 (65)	10 (87)
t _{1/2}	[h]	20.1 (29)	21 (34)	24 (34)	18 (46)	16 (29)
CL/f	[mL/min]	8.8 (29)	9.9 (76)	5.1 (22)	19 (43)	11 (44)
V -/f 4	[L]	14.7 (32)	15 (42)	10 (30)	26 (44)	14 (29)

¹The parameter values in the table are from various studies

² not under high fat conditions meloxicam tablets

4 V₇ /f =Dose/(AUC•K_{el})

Food and Antacid Effects tration of meloxicam capsules following a high fat breakfast (75 g of fat) resulted in mean peak drug levels (i.e., Cmax) being increased by approximately 22% while the extent of absorption (AUC) was unchanged The time to maximum concentration (Tmax) was achieved between 5 and 6 hours. In comparison, neither the The three threads the constraints of the thread of the th with conc omitant administration of antacids. Based on these results, meloxicam oral suspension can be administered without regard to timing of meals or concomitant administration of antacids.

mean volume of distribution (Vss) of meloxicam is approximately 10 L. Meloxicam is ~99.4% bound to human plasma proteins (primarily albumin) within the therapeutic dose range. The fraction of protein binding is independent of drug concentration, over the clinically relevant concentration range, but decreases to ~99% patients with renal disease. Meloxicam penetration into human red blood cells, after oral dosing, is less than 10%. Following a radiolabeled dose, over 90% of the radioactivity detected in the plasma was present as unchanged meloxicam

Meloxicam concentrations in synovial fluid, after a single oral dose, range from 40% to 50% of those in plasma. The free fraction in synovial fluid is 2.5 times higher than in plasma, due to the lower albumin content in synovial fluid as compared to plasma. The significance of this penetration is unknown.

Meloxicam is extensively metabolized in the liver. Meloxicam metabolites include 5'-carboxy meloxicam (60% of dose), from P-450 mediated metabolism formed by oxidation of an intermediate metabolite 5'-hydroxymethyl meloxicam which is also excreted to a lesser extent (9% of dose). In vitro studies indicate that CYP2C9 (cytochrome P450 metabolizing enzyme) plays an important role in this metabolic pathway with a minor contribution of the CYP3A4 isozyme. Patients' peroxidase activity is probably responsible for the other two metabolites which account for 16% and 4% of the administered dose, respectively. All the four netabolites are not known to have any in vivo pharmacological activity.

Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the urine and feces. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and feces (1.6%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6%, and 13% of the does were found in units the form of meloxicam, and the 5⁻-hydrownethyl and 5⁻-carboxy methabolites, respectively. There is significant biliary and/or enteral secretion of the drug. This was demonstrated when oral administration of cholestyramine following a single IV dose of meloxicam decreased the AUC of meloxicam bv 50%.

The mean elimination half-life (t_{1/2}) ranges from 15 hours to 20 hours. The elimination half-life is constant across dose levels indicating linear metabolism within the therapeutic dose range. Plasma clearance ranges from 7 to 9 mL/min.

Specific Populations Pediatric

After single (0.25 mg/kg) dose administration and after achieving steady state (0.375 mg/kg/day), there was a general trend of approximately 30% lower exposure in younger patients (2 to 6 years old) as compared to the older patients (7 to 16 years old). The older patients had meloxicam exposures similar (single dose) or slightly reduced (steady state) to those in the adult patients, when using AUC values normalized to a dose of 0.25 mg/ kg [see Dosage and Administration (2.4)]. The meloxicam mean (SD) elimination half-life was 15.2 (10.1) and 13.0 hours (3.0) for the 2 to 6 year old patients, and 7 to 16 year old patients, respectively.

In a covariate analysis, utilizing population pharmacokinetics body-weight, but not age, was the single predic tive covariate for differences in the meloxicam apparent oral plasma clearance. The body-weight normalized apparent oral clearance values were adequate predictors of meloxicam exposure in pediatric patients.

The pharmacokinetics of meloxicam oral suspension in pediatric patients under 2 years of age have not been

Elderly males (≥65 years of age) exhibited meloxicam plasma concentrations and steady-state pharmacokinetics similar to young males. Elderly females (≥65 years of age) had a 47% higher AUC_{ss} and 32% higher C_{max ss} as compared to younger females (≤55 years of age) after body weight normalization. Despite the marks to compare of young in concentrations in the elderly females, the adverse event profile was comparable for both elderly patient populations. A smaller free fraction was found in elderly female patients in comparison to elderly male patients.

Use in Specific Populations (8.6)1.

Specific Populations (8.7)].

NSAIDs with aspirin [see Drug Interactions (7)].

pharmacokinetics of 30 mg meloxicam.

clinical relevance of this interaction has not been established

ion between digoxin and meloxicam.

new medication is introduced [see Drug Interactions (7)]

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

13 NONCLINICAL TOXICOLOG

14 CLINICAL STUDIES

14.1 Osteoarthritis and Rheumatoid Arthritis

Drug Interaction Studies

Young females exhibited slightly lower plasma concentrations relative to young males. After single doses of 7.5 mg meloxicam, the mean elimination half-life was 19.5 hours for the female group as compared to 23.4 hours for the male group. At steady state, the data were similar (17.9 hours vs 21.4 hours). This pharmacokinetic difference due to gender is likely to be of little clinical importance. There was linearity of pharmacokinetics and no appreciable difference in the C_{max} or T_{max} across genders.

to healthy volunteers. Protein binding of meloxicam was not affected by hepatic impairment. No dosage

adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment (Child-Pugh Class III) have not been adequately studied [see Warnings and Precautions (5.3) and

Meloxicam pharmacokinetics have been investigated in subjects with mild and moderate renal impairment. To

tal drug plasma concentrations of meloxicam decreased and total cleared of meloxicam increased with the degree of renal impairment while free AUC values were similar in all groups. The higher meloxicam clearance

in subjects with renal impairment may be due to increased fraction of unbound meloxicam which is available for hepatic metabolism and subsequent excretion. No dosage adjustment is necessary in patients with mild to moderate renal impairment. Patients with severe renal impairment have not been adequately studied. The use

of meloxicam oral suspension in subjects with severe renal impairment is not recommended [see Dosage and

Following a single dose of meloxicam, the free C_{max} plasma concentrations were higher in patients with renal failure on chronic hemodialysis (1% free fraction) in comparison to healthy volunteers (0.3% free fraction). Hemodialysis did not lower the total drug concentration in plasma; therefore, additional doses are not

essary after hemodialysis. Meloxicam is not dialyzable [see Dosage and Administration (2.1) and Use in

Aspirin: When NSAIDs were administered with aspirin, the protein binding of NSAIDs were reduced, although

the clearance of free NSAID was not altered. When meloxicam is administered with aspirin (1000 mg three times daily) to healthy volunteers, it tended to increase the AUC (10%) and C_{max} (24%) of meloxicam. The

Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of

clinical significance of this interaction is not known. See Table 3 for clinically significant drug interactions of

meloxicam by 50%. This resulted in a decrease in t_{1/2}, from 19.2 hours to 12.5 hours, and a 35% reduction in AUC. This suggests the existence of a recirculation pathway for meloxicam in the gastrointestinal tract. The

Cimetidine: Concomitant administration of 200 mg cimetidine four times daily did not alter the single-dose

after β-acetyldigoxin administration for 7 days at clinical doses. In vitro testing found no protein binding drug

Creased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg twite daily with meloxicam 15 mg QD every day as compared to subjects receiving lithium alone [see Drug Interactions (7)].

Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. Meloxicam did not have a significant

effect on the pharmacokinetics of single doses of methotrexate. In vitro, methotrexate did not displace

Warfarin: The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy

Variation in the electron motion and an electron warrant was added and electron matrix was added and electron of the anti-subjects receiving daily does of warrant hat produced an INR (International Normalized Ratio) between J. and 1.8. In these subjects, meloxicam did not alter warrant pharmacokinetics and the average anticoagulant

effect of warfarin as determined by prothrombin time. However, one subject showed an increase in INR from 1.5 to 2.1. Caution should be used when administering meloxicam oral suspension with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a

here was no increase in tumor incidence in long-term carcinogenicity studies in rats (104 weeks) and mice

mice (up to 0.5-and 2.6-times, respectively, the maximum recommended human dose [MRHD] of 15 mg/day

(99 weeks) administered meloxicam at oral doses up to 0.8 mg/kg/day in rats and up to 8.0 mg/kg/day in

Meloxicam was not mutagenic in an Ames assay, or clastogenic in a chromosome aberration assay with

Meloxicam did not impair male and female fertility in rats at oral doses up to 9 mg/kg/day in males and 5 mg/

kg/day in females (up to 5.8-and 3.2-times greater, respectively, than the MRHD based on BSA comparison

The use of meloxicam for the treatment of the signs and symptoms of osteoarthritis of the knee and hip

assessment, patient pain assessment, and total WOMAC score (a self-administered questionnaire addre

pain, function, and stiffness). Patients on meloxicam 7.5 mg daily and meloxicam 15 mg daily showed

The use of meloxicam for the management of signs and symptoms of osteoarthritis was evaluated in six

double-blind, active-controlled trials outside the U.S. ranging from 4 weeks' to 6 months' duration. In these

trials, the efficacy of meloxicam, in doses of 7.5 mg/day and 15 mg/day, was comparable to piroxicam 20

The use of meloxicam for the treatment of the signs and symptoms of rheumatoid arthritis was evaluated in

12-week, double-blind, controlled multinational trial. Meloxicam (7.5 mg, 15 mg, and 22.5 mg daily) was

/day and diclofenac SR 100 mg/day and consistent with the efficacy seen in the U.S. trial

was evaluated in a 12-week double-bind or the signs and symptoms of obtaining or the hore and may was evaluated in a 12-week double-bind (controlled trial. Meloxican 3/37 bing, 7.5 bing, and 15 bing daily) was compared to placebo. The four primary endpoints were investigator's global assessment, patient global

kicam from its human serum binding sites [see Drug Interactions (7)].

kicam oral suspension based on body surface area [BSA] comparison).

human lymphocytes and an in vivo micronucleus test in mouse bone marrow.

significant improvement in each of these endpoints compared with placebo.

Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin

Lithium: In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were in-

Administration (2.5), Warnings and Precautions (5.6) and Use in Specific Populations (8.7)].

Hepatic Impairment Following a single 15 mg dose of meloxicam there was no marked difference in plasma concentrations in patients with mild (Child-Pugh Class I) or moderate (Child-Pugh Class II) hepatic impairment compared

Renal Impairmen

compared to placebo. The primary endpoint in this study was the ACR20 response rate, a composite measure of clinical, laboratory, and functional measures of RA response. Patients receiving melasional and an and the second seco benefit was observed with the 22.5 mg dose compared to the 15 mg dose.

14.2 Juvenile Rheumatoid Arthritis (JRA) Pauciarticular and Polyarticular Course

double-blind, parallel-arm, active-controlled trials.

of meloxicam and 15 mg/kg/day of naproxen.

16 HOW SUPPLIED/STORAGE AND HANDLING

Keep oral suspension container tightly closed.

17 PATIENT COUNSELING INFORMATION

Keep this and all medications out of the reach of children.

and periodically during the course of ongoing therapy.

provider immediately [see Warnings and Precautions (5.1)].

Gastrointestinal Bleeding, Ulceration, and Perforation

and Precautions (5.2)].

Heart Failure and Edema

and Precautions (5.5)].

Anaphylactic Reactions

Female Fertility

Fetal Toxicity

Made in Canada

C-A235

Serious Skin Reactions, including DRESS

Avoid Concomitant Use of NSAIDs

Use of NSAIDs and Low-Dose Aspirin

© 2022 Emerald Therapeutics, LLC

their healthcare provider [see Drug Interactions (7)].

Hepatotoxicity

(5.3)].

7.5 mg meloxicam in 5 ml

The use of meloxicam for the treatment of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age and older was evaluated in two 12-week,

Both studies included three arms: naproxen and two doses of meloxicam. In both studies, meloxicam dosing began at 0.125 mg/kg/day (7.5 mg maximum) or 0.25 mg/kg/day (15 mg maximum), and naproxen dosing began at 10 mg/kg/day. One study used these doses throughout the 12-week dosing period, while the other incorporated a titration after 4 weeks to doses of 0.25 mg/kg/day and 0.375 mg/kg/day (22.5 mg maximum) The efficacy analysis used the ACR Pediatric 30 responder definition, a composite of parent and investigator assessments, counts of active joints and joints with limited range of motion, and erythrocyte sedimentation adecommences before the component of the set of the set

Meloxicam oral suspension, USP is available as a yellowish green tinged viscous oral suspension containing

Meloxicam oral suspension, USP, 7.5 mg/5 mL: NDC 72919-124-10; Bottles of 100 mL

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room

Advise the patient to read the FDA-approved patient labeling (Medication Guide) that accompanies each

- Inform patients, families or their caregivers of the following information before initiating therapy with an NSAID
- Cardiovascular Thrombotic Events Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to report any of these symptoms to their healthcare

Advise patients to report symptoms of ulcerations and bleeding, including epigastric pain, dyspepsia, melena, and hematemesis to their healthcare provider. In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, inform patients of the increased risk for the signs and symptoms of Gl bleeding *[see Warnings*

Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If these occur, instruct patients to stop meloxicam oral suspension and seek immediate medical therapy [see Warnings and Precautions

Advise patients to be aler for the symptoms of congestive heart failure including shortness of breath, unex-plained weight gain, or edema and to contact their healthcare provider if such symptoms occur [see Warnings

Inform patients of the signs of an anaphylactic reaction (e.g., difficulty breathing, swelling of the face or throat). Instruct patients to seek immediate emergency help if these occur [see Contraindications (4) and Warnings and Precautions (5.7)].

Advise patients to stop taking meloxicam oral suspension immediately if they develop any type of rash or fever and to contact their healthcare provider as soon as possible [see Warnings and Precautions (5.9), (5.10)].

Advise females of reproductive potential who desire pregnancy that NSAIDs, including meloxicam oral suspension, may be associated with a reversible delay in ovulation [see Use in Specific Populations (8.3)].

Inform pregnant women to avoid use of meloxicam oral suspension and other NSAIDs starting at 30 weeks gestation because of the risk of the premature closing of the fetal ductus arteriosus. If treatment with meloxicam oral suspension is needed for a pregnant woman between about 20 to 30 weeks gestation, advise her Warnings and Precautions (5.11) and Use in Specific Populations (8.1)].

Inform patients that the concomitant use of meloxicam oral suspension with other NSAIDs or salicylates (e.g., diffunisal, salsalate) is not recommended due to the increased risk of gastrointestinal toxicity, and little or no increase in efficacy [see Warnings and Precautions (5.2) and Drug Interactions (7)]. Alert patients that NSAIDs may be present in "over the counter" medications for treatment of colds, fever, or insomnia.

Inform patients not to use low-dose aspirin concomitantly with meloxicam oral suspension until they talk to

For current prescribing information, call Emerald Therapeutics, LLC at 800-970-1991.

Manufactured for Emerald Therapeutics, LLC, Birmingham, AL 35209 USA

Anti-infla	he most important information I should know about medicines called Nonsi
104105 (immatory Drugs (NSAIDs)? ian cause serious side effects, including:
in treat	sed risk of a heart attack or stroke that can lead to death. This risk may happ ment and may increase: increasing doses of NSAIDs
• with Do not ta graft (CA	longer use of NSAIDs ke NSAIDs right before or after a heart surgery called a "coronary artery by BG)." Avoid taking NSAIDs after a recent heart attack, unless your healthca
	tells you to. You may have an increased risk of another heart attack if you t ifter a recent heart attack.
 Increa from t 	sed risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube he mouth to the stomach), stomach and intestines: me during use
 with 	out warning symptoms
The risk	may cause death of getting an ulcer or bleeding increases with:
	history of stomach ulcers, or stomach or intestinal bleeding with use of NSAIDs g medicines called "corticosteroids", "anticoagulants", "SSRIs", or "SNRIs"
 incre 	asing doses of NSAIDs er use of NSAIDs
• smol	ring
 older 	
 poor adva 	health nced liver disease
	ting problems :hould only be used:
• exact	tly as prescribed e lowest dose possible for your treatment
	e shortest time needed
VSAIDs ar	NSAIDs? e used to treat pain and redness, swelling, and heat (inflammation) from medical cor
	ifferent types of arthritis, menstrual cramps, and other types of short-term pain.
Do not ta	uld not take NSAIDs? ike NSAIDs:
 if you NSAIDs 	I have had an asthma attack, hives, or other allergic reaction with aspirin or any othe 3.
• right	before or after heart bypass surgery.
Before ta including	king NSAIDs, tell your healthcare provider about all of your medical conditi i if you:
 have 	liver or kidney problems high blood pressure
 have 	asthma
	regnant or plan to become pregnant. Taking NSAIDs at about 20 weeks of pregnancy ay harm your unborn baby. If you need to take NSAIDs for more than 2 days when yo
	n 20 and 30 weeks of pregnancy, your healthcare provider may need to monitor the in your womb and around your baby. You should not take NSAIDs after about
30 we	eks of pregnancy. reastfeeding or plan to breast feed.
Tell your	healthcare provider about all of the medicines you take, including prescript
nedicines	he-counter medicines, vitamins or herbal supplements. NSAIDs and some oth can interact with each other and cause serious side effects.
Do not st	art taking any new medicine without talking to your healthcare provider fir
Nhat are	the possible side effects of NSAIDs? an cause serious side effects, including:
	at is the most important information I should know about medicines called idal Anti-inflammatory Drugs (NSAIDs)?"
	ida Ana imaminatory brago (itoAbbo).
• new	or worse high blood pressure
• new • heart • liver	failure problems including liver failure
 Nonstero new heart liver kidne 	failure problems including liver failure ay problems including kidney failure
Nonstera • new • heart • liver • kidne • low r • life-tt	failure problems including liver failure ey problems including kidney failure ed blood cells (anemia) nreatening skin reactions
Nonstero • new • heart • liver • kidne • low r • life-tt • life-tt • Othe	failure problems including liver failure y problems including kidney failure ed blood cells (anemia) rreatening allergic reactions rreatening allergic reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heard
Nonstero new heard liver kidne low r life-tt life-tt Othe nausea Get emer	tailure problems including liver failure ay problems including kidney failure ed blood cells (anemia) nreatening allergic reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart y comiting, and dizziness. gency help right away if you get any of the following symptoms:
Nonstero new heard liver kidne low r life-tt life-tt Othe nausea Get emer	failure problems including liver failure y problems including kidney failure ed blood cells (anemia) rreatening alkin reactions rreatening alkin reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart , vomiting, and dizziness. gency help right away if you get any of the following symptoms: ness of breath or trouble breathing
Nonstero • new • heart • liver • kidne • low r • life-tt • life-tt • life-tt • othe nausea Get emer • short • ches • weak	tailure problems including liver failure ay problems including kidney failure ed blood cells (anemia) mreatening allergic reactions restening allergic reactions restening allergic reactions resten of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart , vomiting, and dizziness. regncy help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain eness in one part or side of your body
Nonstero • new • heart • liver • kidne • low r • life-tt • life-tt • life-tt • othe nausea Get emer • short • ches • weak • slurre • swell	tailure problems including liver failure by problems including kidney failure ed blood cells (anemia) preatening skin reactions preatening allergic reactions reater side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart , vomiting, and dizziness. gency help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain ness in one part or side of your body ad speech ing of the face or throat
Nonstero • new • heart • liver • kidne • low r • life-tt • life-tt • othe nausea Get emer • short • ches • weak • suveil Stop taki following	failure roblems including liver failure y problems including kidney failure ed blood cells (anemia) rreatening allergic reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart y, vomiting, and dizziness. gency help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain ness in one part or side of your body ed speech ing of the face or throat ng your NSAID and call your healthcare provider right away if you get any of symptoms:
Nonstero • new • heart • liver • kidne • low r • life-tt • short • short • short • short • life-tt • life-tt • short • short • life-tt • life-tt • short • short • life-tt • life-tt • life-tt • life-tt • short • life-tt • life-tt	tailure problems including liver failure by problems including kidney failure ed blood cells (anemia) rreatening skin reactions rreatening allergic reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart , vomiting, and dizziness. gency help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain ness in one part or side of your body ad speech ing of the face or throat ing your NSAID and call your healthcare provider right away if you get any of s ymptoms: ea
Nonstero • new • heart • liver • kidne • low r • life-tt • short • ches • weak • slurre • swell Stop takit following • naus	failure roblems including liver failure y problems including kidney failure ed blood cells (anemia) rreatening alkin reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart y, vomiting, and dizziness. gency help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain ness in one part or side of your body ed speech ing of the face or throat ing your NSAID and call your healthcare provider right away if you get any of symptoms: ea • tired or weaker than usual tea
Nonstero new heart liver kidne low r life-ti life-ti life-ti life-ti life-ti life-ti life-ti life-ti life-ti life-ti source s	tailure trailure problems including liver failure ed blood cells (anemia) rreatening skin reactions rreatening allergic reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart , vomiting, and dizziness. gency help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain ness in one part or side of your body ad speech ing of the face or throat ing your NSAID and call your healthcare provider right away if you get any of symptoms: ea tried or weaker than usual tea g g
Nonstero • new • heart • liver • kidne • low r • liver • kidne • liver • kidne • liver • kidne • liver • liver • liver • liver • othe • nausea Get emer • short • ches • weal • short • nause • more • diarrit • itchir • your • inde-the	<pre>tailure trailure trailure</pre>
 Nonstero new newarts liver liver liver liver liver life-th life-th<!--</td--><td><pre>tailure trailure trailure</pre></td>	<pre>tailure trailure trailure</pre>
Vonstera • new • heartan • liver •	<pre>failure failure problems including liver failure y problems including kidney failure ed blood cells (anemia) rreatening allergic reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart y, vomiting, and dizziness. gency help right away if you get any of the following symptoms: neess of breath or trouble breathing t pain neess in one part or side of your body ad speech ing of the face or throat g your NSAID and call your healthcare provider right away if you get any of skin or eyes look yellow estion or stomach pain ke symptoms t blood is blood in your bowel movement or it is black and sticky like tar ual weight gain</pre>
Vonstera • new • heart • liver • li	failure roblems including liver failure y problems including kidney failure ed blood cells (anemia) rreatening allergic reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart y, vomiting, and dizziness. gency help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain ness in one part or side of your body ad speech ing of the face or throat ing your NSAID and call your healthcare provider right away if you get any of symptoms: ea tired or weaker than usual hea g g skin or eyes look yellow estion or stomach pain ke symptoms t blood is blood in your bowel movement or it is black and sticky like tar
Nonstera • new • heartan • liver • kidnur nu • kidnur • kidnur • kidnur • kidnur • kite-tt • kite-tt	<pre>tailure trailure trailure</pre>
Nonstera • new • heart • liver • kidnur nu • liver • kidnur • liver • liver	<pre>failure failure failure failure problems including liver failure gy problems including kidney failure ed blood cells (anemia) rreatening alkin reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart y, vomiting, and dizziness. gency help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain ness in one part or side of your body d speech ing of the face or throat ing your NSAID and call your healthcare provider right away if you get any of skin or eyes look yellow estion or stomach pain ke symptoms t blood is blood in your bowel movement or it is black and sticky like tar ual weight gain rash or blisters with fever ing of the arms, legs, hands and feet ke too much of your NSAID, call your healthcare provider or get medical help ay. not all the possible side effects of NSAIDs. For more information, ask your healthcare </pre>
Nonstera • new • heart • liver • kidnur • liver • kidnur • liver • kidnur • life-tt • lif	<pre>failure failure failure problems including liver failure y problems including kidney failure ed blood cells (anemia) rreatening alkin reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart y, vomiting, and dizziness. gency help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain ness in one part or side of your body ad speech ing of the face or throat ing your NSAID and call your healthcare provider right away if you get any of skin or eyes look yellow estion or stomach pain ke symptoms t blood is blood in your bowel movement or it is black and sticky like tar ual weight gain rash or blisters with fever ing of the arms, legs, hands and feet se too much of your NSAID, call your healthcare provider or get medical help ay.</pre>
Nonstera • new • heart • liver • kidnur • liver • kidnur • liver • kidnur • life-tt • lif	failure failure failure y problems including liver failure y problems including liver failure y problems including kidney failure ed blood cells (anemia) treatening allerigic reactions treatening allerigic reactions treatening allerigic reactions treatening allerigic reactions the following symptoms: ness of breath or trouble breathing train inclusion of the following symptoms: ness of breath or trouble breathing train inclusion of the following symptoms: ness of breath or trouble breathing train inclusion of the following symptoms: ness of breath or trouble breathing train inclusion of the following symptoms: ness in one part or side of your body ad speech ing of the face or throat ing your NSAID and call your healthcare provider right away if you get any of skin or eyes look yellow estion or stomach pain to side of your body is blood in your bowel movement or it is black and sticky like tar ual weight gain rash or blisters with fever ing of the arms, legs, hands and feet tec too much of your NSAID, call your healthcare provider or get medical hell ay. In tall the possible side effects of NSAIDs. For more information, ask your healthcare provider or bords are pharmacist about NSAIDs.
Nonstera • new • heart • liver • kidnar • liver • kidnar • liver • kidnar • liver • kidnar • liver • kidnar • liver • liver • liver • liver • liver • liver • onsea • sweak • ches • sweak • sweak • sweak • sweak • sweak • sweak • ches • sweak • sweak • sweak • sweak • ches • sweak • sweak • ches • ch	<pre>failure failure failure y problems including liver failure y problems including liver failure y problems including kidney failure ed blood cells (anemia) rreatening allergic reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart , vomiting, and dizziness. gency help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain ness in one part or side of your body ad speech ing of the face or throat ing your NSAID and call your healthcare provider right away if you get any of symptoms: ea iterd or weaker than usual hea ig g skin or eyes look yellow estion or stomach pain estymptoms t blood is blood in your bowel movement or it is black and sticky like tar ual weight gain rash or blisters with fever ing of the arms, legs, hands and feet ec too much of your NSAID, call your healthcare provider or get medical help ay. not all the possible side effects of NSAIDs. For more information, ask your healthcare pharmacist about NSAIDs: cormation about NSAIDs:</pre>
Nonstera • new • heart • liver • kidowr • liver • kidowr • liver • kidowr • liver • kidowr • liver • kidowr • life-th • Othernauseause • Othernauseause • Othernauseause • Othernauseause • Othernauseauseause • Othernauseauseauseauseauseauseauseauseauseause	<pre>failure failure problems including liver failure problems including liver failure problems including kidney failure ed blood cells (anemia) rreatening allergic reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart , vomiting, and dizziness. gency help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain ness in one part or side of your body d speech ing of the face or throat ng your NSAID and call your healthcare provider right away if you get any of skin or eyes look yellow estion or stomach pain estion or blisters with fever ing of the arms, legs, hands and feet estoo much of your NSAIDs. for medical advice about side effects. You may report side effects to FDA at A-1088. </pre>
Nonstera • new • heart • liver • kidnic • liver • kidnic • liver • kidnic • liver • kidnic • liver • liver • liver • liver • liver • liver • liver • liver • liver • ones • sweaka • ches • sweaka • ches • sweaka • sweaka • ches • sweaka • ches • sweaka • sweaka • ches • sweaka • sweaka • ches • sweaka • sweaka	<pre>failure failure problems including liver failure problems including liver failure problems including kidney failure ed blood cells (anemia) rreatening allergic reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart , vomiting, and dizziness. gency help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain ness in one part or side of your body d speech ing of the face or throat ng your NSAID and call your healthcare provider right away if you get any of skin or eyes look yellow estion or stomach pain estion or blisters with fever ing of the arms, legs, hands and feet estoo much of your NSAIDs. for medical advice about side effects. You may report side effects to FDA at A-1088. </pre>
Nonstera • new • heart • liver • ones • sweaka • chese • sweaka • sweaka • sweaka • chese • sweaka • sweaka • sweaka • sweaka • chese • sweaka • sweaka • chese • sweaka • sweaka • ones • sweaka • chese • sweaka • ones • sweaka • ones • ones • ones • sweaka • ones •	<pre>failure failure failure problems including liver failure problems including kidney failure ed blood cells (anemia) rreatening alkin reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart womiting, and dizziness. gency help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain ness in one part or side of your body ad speech ing of the face or throat ing your NSAID and call your healthcare provider right away if you get any of symptoms: ea if ere or weaker than usual hea g g skin or eyes look yellow estion or stomach pain es your power look yellow estion or stomach pain es with fever ing of the arms, legs, hands and feet te too much of your NSAID, call your healthcare provider or get medical help ay. not all the possible side effects of NSAIDs. For more information, ask your healthcare pharmacist about NSAIDs. s an NSAID but it does not increase the chance of a heart attack. Aspirin can cause I in, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestin sAIDs are sold in lower doses without a prescription (over-the-counter). Talk to your lear before using over-the-counter NSAIDs for more than 10 days. </pre>
Nonstera • new • heart • liver • li	<pre>failure failure problems including liver failure problems including kidney failure ed blood cells (anemia) rreatening allergic reactions r side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart , vomiting, and dizziness. gency help right away if you get any of the following symptoms: neess of breath or trouble breathing t pain neess in one part or side of your body d speech ing of the face or throat ng your NSAID and call your healthcare provider right away if you get any of symptoms: ea ea ea titred or weaker than usual hea ig skin or eyes look yellow estion or stomach pain ex symptoms t blood is blood</pre>
Nonstera • new • heart • liver • li	<pre>failure failure failure failure failure for problems including liver failure for problems including liver failure for the failure for the</pre>
Nonstera • new • heart • liver • short • short • lover • short • lover • liver •	failure failure problems including liver failure y problems including liver failure y problems including kidney failure ed blood cells (anemia) treatening allergic reactions for side effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart, vomiting, and dizziness. gency help right away if you get any of the following symptoms: nees of breath or trouble breathing t pain iness in one part or side of your body ad speech ing of the face or throat ag your NSAID and call your healthcare provider right away if you get any of section or somach pain kees y proteins. ea time of vexes than usual hea 19 skin or eyes look yellow estion or stomach pain kee yellow estion or stomach pain kee yellow tiblood is blood is blood is blood is blood is blood in your bowel movement or it is black and sticky like tar ual weight gain rank or blisters with fever ing of the arms, legs, hands and feet ce to much of your NSAID, call your healthcare provider or get medical help ay. not all the possible side effects of NSAIDs. For more information, ask your healthcare provider or medical advice about NSAIDs. bornation about NSAIDs: as an NSAID but it does not increase the chance of a heart attack. Aspirin can cause I in, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intesting SAIDs are solid in lower doses without a prescription (over-the-counter). Talk to your lar before using over-the-counter NSAIDs for more than 10 days. rormation about the safe and effective use of NSAIDs Aron tall the condition for which it was not prescribed. Do not give NSAIDs to other pe
Nonstera • new • heart • liver • li	<pre>failure failure failure groblems including liver failure groblems including liver failure groblems including kidney failure ed blood cells (anemia) rreatening alkin reactions rreatening alkin reactions rside effects of NSAIDs include: stomach pain, constipation, diarrhea, gas, heart , vomiting, and dizziness. gency help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain including liver failure grow help right away if you get any of the following symptoms: ness of breath or trouble breathing t pain ing of the face or throat ing your NSAID and call your healthcare provider right away if you get any of symptoms: ea tired or weaker than usual hea ig skin or eyes look yellow estion or stomach pain estion or stomach pain estion or stomach pain estion or stomach pain estion or bibters with fever ing of the arms, legs, hands and feet se too much of your NSAID, call your healthcare provider or get medical hell ay. not all the possible side effects of NSAIDs. For more information, ask your healthcare r pharmacist about NSAIDs. Solor medical advice about side effects. You may report side effects to FDA at A-1088. rormation about the safe and effective use of NSAIDs are sometimes prescribed for purposes other than 10 days. formation about the safe and effective use of NSAIDs are sometimes prescribed for purposes other than those listed in a Medication Guid SAIDs are solid in lower doese without a prescription. (over the-counter), Talk to your der before using over-the-counter NSAIDs for more than 10 days. </pre>

© 2022 Emerald Therapeutics, LLC

is Medication Guide has been approved by the U.S. Food and Drug Administration Revised: April 2022